ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

quizartinib

Also written as “Quizartinib”, “AC220” and “Quizartinib High Dose”.

Its studies are mostly in Leukemia, Myeloid, Acute, led by 2 companies.

Drug pageQuizartinib: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 15, 201422 company-led studies, 5 open or runningNext primary completion: May 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyo214 open or runningphase 3since Jan 15, 2014Apr 17, 2007May 1, 2027phase 2 · NCT03793478
Kura Oncologyits history only11 open or runningphase 1since Feb 9, 2023Feb 9, 2023Apr 2030phase 1 · NCT05735184

Also a collaborator on its studies: Quotient Sciences and Ambit Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Daiichi Sankyo only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Apr 17, 2007.

  1. Jan 15, 2014Phase 3 study in Leukemia, Myeloid, AcuteNCT02039726 · 367 enrolled · United States, Australia, Belgium and more
  2. Jan 22, 2016Phase 3 study in Leukemia, Myeloid, AcuteNCT02668653 · 539 enrolled · United States, Argentina, Australia and more
  3. Feb 2, 2016Phase 1 study in Leukemia, Myeloid, AcuteNCT02675478 · 17 enrolled · Japan
  4. Jul 13, 2016Phase 1 study in Leukemia, Myeloid, AcuteNCT02834390 · 7 enrolled · Japan
  5. Dec 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteNCT02984995 · 37 enrolled · Japan
  6. May 17, 2018Phase 1 study in Leukemia, Myeloid, AcuteNCT03552029 · 10 enrolled · United States
  7. Oct 18, 2018Phase 1 study in Leukemia, Myeloid, AcuteNCT03723681 · 7 enrolled · China
  8. Jan 2, 2019Phase 2 study in Leukemia, Myeloid, AcuteNCT03793478 · 65 enrolled · United States, Belgium, Canada and more
  9. Jul 2, 20202 phase 1 studiesNCT04459598, NCT04473664
  10. Jul 2, 2020Early phase 1 study in Healthy SubjectsNCT04459585 · 20 enrolled · United States
  11. Mar 5, 2021Phase 1 study in Healthy SubjectsNCT04796831 · 8 enrolled · United Kingdom
  12. Aug 14, 2024Phase 3 study in LeukemiaNCT06578247 · 700 enrolled · United States, Australia, Austria and more
  13. Dec 13, 20243 phase 1 studiesNCT06772246, NCT06740825, NCT06740799
  14. Feb 7, 2025Phase 2 study in Leukemia, Myeloid, AcuteNCT06824168 · 130 planned · United States, Australia, Brazil and more

Ahead

  1. May 1, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT03793478
  2. Jun 6, 2028Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT06824168
  3. Jun 26, 2030Primary completion: phase 3 study in LeukemiaNCT06578247

TargetBeta

“Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor”ChEMBL 37, by rule

Studies

All 21 Daiichi Sankyo leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06824168Leukemia, Myeloid, Acute · United States, Australia, Brazil and more2RecruitingJun 6, 2028130
NCT06772246Healthy Subjects · United States1CompletedJun 12, 202570
NCT06740825Healthy Subjects · United States1CompletedDec 9, 202432
NCT06740799Hepatic Impairment · United States1RecruitingOct 31, 202612
NCT06578247Leukemia · United States, Australia, Austria and more3Active, not recruitingJun 26, 2030700
NCT04796831Healthy Subjects · United Kingdom1CompletedJun 11, 20218
NCT04473664Hepatic Impairment · United States1CompletedJul 22, 202112
NCT04459598Healthy Subjects · United States1CompletedOct 14, 202032
NCT04459585Healthy Subjects · United StatesEarly 1CompletedOct 20, 202020
NCT03793478Leukemia, Myeloid, Acute · United States, Belgium, Canada and more2Active, not recruitingMay 1, 202765
NCT03723681Leukemia, Myeloid, Acute · China1CompletedMar 3, 20227
NCT03552029Leukemia, Myeloid, Acute · United States1TerminatedApr 1, 202110
NCT02984995Leukemia, Myeloid, Acute · Japan2CompletedMar 28, 201837
NCT02834390Leukemia, Myeloid, Acute · Japan1CompletedOct 19, 20177
NCT02675478Leukemia, Myeloid, Acute · Japan1CompletedNov 13, 201817
NCT02668653Leukemia, Myeloid, Acute · United States, Argentina, Australia and more3CompletedAug 13, 2021539
NCT02039726Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3CompletedFeb 22, 2018367
NCT01565668Leukemia, Myeloid, Acute · United States, France, Italy and more2CompletedMar 201576
NCT01468467Leukemia, Myeloid, Acute · United States1CompletedMar 201513
NCT01390337Leukemia, Myeloid, Acute · United States1CompletedFeb 201519
NCT00462761Leukemia, Myeloid, Acute · United States, Georgia1CompletedMar 200976

How it is read

Names in the registry

  • “Quizartinib”, 15 entries
  • “AC220”, 5 entries
  • “Quizartinib High Dose”, 1 entry
  • “Quizartinib Low Dose”, 1 entry
  • “Quizartinib dihydrochloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.